NextGen News
NextGen Pharma is proud to welcome our newest client:
AnaBios Corporation, based in San Diego, CA, is a distinctive Contract Research Organization that offers exclusive Ex- Vivo assays utilizing viable human tissues collected from US organ transplant centers. AnaBios’ expert procurement & scientific personnel have experience in collecting and utilizing over 2000 dorsal root ganglia (DRGs) and 300 hearts from organ donors. With the capacity to recover 20,000 DRG’s and 300 hearts per year, AnaBios could help drive and fully support your efficacy and safety evaluations for CV, Pain and CNS therapies (Human brain availability ~Q3 2012). A rigid quality assurance and functional qualification process ensures that these tissues provide the best known models of human responses to compounds in development. This novel Translational platform creates a paradigm shift in the pharmaceutical industry by bridging the knowledge gap between preclinical data & failed clinical outcomes. Human tissue models can enable more accurate compound and dose selection, and can de-risk safety and efficacy liabilities prior to clinical trials. AnaBios’ validated models, combined with data analysis and AnaBios’ comprehensive databases, can potentially allow pharmaceutical companies to efficiently advance their drug development programs with a greater certainty at a fraction of the cost and time compared to current development paradigms.
Complete Range of Outsourcing Options
NextGen Pharma Technologies, Inc. provides sales representation for innovative and niche CROs to Pharmaceutical and Biotechnology R&D decision makers. NextGen offers a complete range of outsourcing options - from discovery support through IND/NDA support and beyond. NextGen represents companies with new innovative technologies that improve lead optimization and drug candidate selection using: Predictive ADME; in vivo efficacy; safety pharmacology, xenografts; behavioral pharmacology; unique animal and surgical models; BBB; mouse with a human liver; Indications Discovery Screening, drug development support such a GLP, Toxicology, ADME - rodents to NHP’s; formulation development; clinical supply manufacturing; GLP bioanalytical support; GLP protein and peptide analysis. These technologies can reduce development time and cost. In these uncertain economic times, NG clients offer a lower cost/higher value alternative to large multi-disciplined CROs.
For an overview of NextGen companies, click here.
